WithdrawnNCT07084831
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
Researchers are studying Xanomeline/trospium to find out how it affects memory, attention and other thinking skills in adults with schizophrenia.
Medication studyAges 18–55Multiple countries
Understand this study
What is this study about?
Researchers are studying Xanomeline/trospium to find out how it affects memory, attention and other thinking skills in adults with schizophrenia.
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
- Listed locations
- Innsbruck and 15 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: January 1, 2027
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- European Group for Research In Schizophrenia
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Belgium, Austria, Czechia, ...
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT07084831
- Official title
Show the full official title
A Prospective, Open-label, Single-arm, Multicenter Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
Recruitment & locations
WithdrawnThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Innsbruck, Austria · Leuven, Belgium · Klecany, Czechia
14 more locations
- Glostrup Municipality, Denmark
- Augsburg, Germany
- Cologne, Germany
- Mannheim, Germany
- München, Germany
- Budapest, Hungary
- Ramat Gan, Israel
- Naples, Italy
- Torino, Italy
- Groningen, Netherlands
- Barcelona, Spain
- Madrid, Spain
- Seville, Spain
- Czechia
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are studying Xanomeline/trospium to find out how it affects memory, attention and other thinking skills in adults with schizophrenia.
Who is behind this study?
The study sponsor is European Group for Research In Schizophrenia.
Does this study involve medication?
Yes. The study involves medication, including Xanomeline/trospium.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as withdrawn.
